ID   ARI4A_HUMAN             Reviewed;        1257 AA.
AC   P29374; Q15991; Q15992; Q15993;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 3.
DT   07-APR-2021, entry version 190.
DE   RecName: Full=AT-rich interactive domain-containing protein 4A;
DE            Short=ARID domain-containing protein 4A;
DE   AltName: Full=Retinoblastoma-binding protein 1;
DE            Short=RBBP-1;
GN   Name=ARID4A; Synonyms=RBBP1, RBP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I), INTERACTION WITH RB1, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION, AND VARIANT ALA-779.
RX   PubMed=8414517;
RA   Fattaey A.R., Helin K., Dembski M.S., Dyson N., Harlow E., Vuocolo G.A.,
RA   Hanobik M.G., Haskell K.M., Oliff A., Defeo-Jones D., Jones R.E.;
RT   "Characterization of the retinoblastoma binding proteins RBP1 and RBP2.";
RL   Oncogene 8:3149-3156(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 338-1257 (ISOFORMS I; II AND III),
RP   INTERACTION WITH RB1, SUBCELLULAR LOCATION, AND ALTERNATIVE SPLICING.
RX   PubMed=8455946;
RA   Otterson G.A., Kratzke R.A., Lin A.Y., Johnston P.G., Kaye F.J.;
RT   "Alternative splicing of the RBP1 gene clusters in an internal exon that
RT   encodes potential phosphorylation sites.";
RL   Oncogene 8:949-957(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 855-1203 (ISOFORM I).
RX   PubMed=1857421; DOI=10.1038/352251a0;
RA   Defeo-Jones D., Huang P.S., Jones R.E., Haskell K.M., Vuocolo G.A.,
RA   Hanobik M.G., Huber H.E., Oliff A.;
RT   "Cloning of cDNAs for cellular proteins that bind to the retinoblastoma
RT   gene product.";
RL   Nature 352:251-254(1991).
RN   [5]
RP   IDENTIFICATION IN A COMPLEX WITH SIN3A; SIN3B; HDAC1; HDAC2; SAP30; BRMS1;
RP   RBBP4 AND RBBP7.
RX   PubMed=14581478; DOI=10.1074/jbc.m307969200;
RA   Meehan W.J., Samant R.S., Hopper J.E., Carrozza M.J., Shevde L.A.,
RA   Workman J.L., Eckert K.A., Verderame M.F., Welch D.R.;
RT   "Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with
RT   retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase
RT   complex and represses transcription.";
RL   J. Biol. Chem. 279:1562-1569(2004).
RN   [6]
RP   INTERACTION WITH ARID4B.
RX   PubMed=17043311; DOI=10.1101/gad.1452206;
RA   Wu M.Y., Tsai T.F., Beaudet A.L.;
RT   "Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic
RT   modifications and suppresses an imprinting defect in the PWS/AS domain.";
RL   Genes Dev. 20:2859-2870(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-676 AND SER-1109, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-716; SER-864 AND SER-1145,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   INTERACTION WITH AR.
RX   PubMed=23487765; DOI=10.1073/pnas.1218318110;
RA   Wu R.C., Jiang M., Beaudet A.L., Wu M.Y.;
RT   "ARID4A and ARID4B regulate male fertility, a functional link to the AR and
RT   RB pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:4616-4621(2013).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-481, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [16]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-481 AND LYS-718, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-513; LYS-718; LYS-738 AND
RP   LYS-759, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [18]
RP   STRUCTURE BY NMR OF 170-273.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RBB1NT domain of human RB(Retinoblastoma)-
RT   binding protein 1.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [19] {ECO:0007744|PDB:2LCC}
RP   STRUCTURE BY NMR OF 568-635, DOMAIN, AND MUTAGENESIS OF TYR-583; TYR-592;
RP   TYR-612; TRP-615 AND TYR-619.
RX   PubMed=22247551; DOI=10.1074/jbc.m111.299149;
RA   Gong W., Zhou T., Mo J., Perrett S., Wang J., Feng Y.;
RT   "Structural insight into recognition of methylated histone tails by
RT   retinoblastoma-binding protein 1.";
RL   J. Biol. Chem. 287:8531-8540(2012).
RN   [20] {ECO:0007744|PDB:2MAM}
RP   STRUCTURE BY NMR OF 4-121, AND DNA-BINDING.
RX   PubMed=24379399; DOI=10.1074/jbc.m113.501940;
RA   Gong W., Wang J., Perrett S., Feng Y.;
RT   "Retinoblastoma-binding protein 1 has an interdigitated double Tudor domain
RT   with DNA binding activity.";
RL   J. Biol. Chem. 289:4882-4895(2014).
RN   [21] {ECO:0007744|PDB:6BPH}
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 568-635, AND DOMAIN.
RX   PubMed=29408527; DOI=10.1016/j.bbrc.2018.02.016;
RA   Lei M., Feng Y., Zhou M., Yang Y., Loppnau P., Li Y., Yang Y., Liu Y.;
RT   "Crystal structure of chromo barrel domain of RBBP1.";
RL   Biochem. Biophys. Res. Commun. 496:1344-1348(2018).
CC   -!- FUNCTION: DNA-binding protein which modulates activity of several
CC       transcription factors including RB1 (retinoblastoma-associated protein)
CC       and AR (androgen receptor) (By similarity). May function as part of an
CC       mSin3A repressor complex (PubMed:14581478). Has no intrinsic
CC       transcriptional activity (By similarity). Plays a role in the
CC       regulation of epigenetic modifications at the PWS/AS imprinting center
CC       near the SNRPN promoter, where it might function as part of a complex
CC       with RB1 and ARID4B (By similarity). Involved in spermatogenesis,
CC       together with ARID4B, where it acts as a transcriptional coactivator
CC       for AR and enhances expression of genes required for sperm maturation.
CC       Regulates expression of the tight junction protein CLDN3 in the testis,
CC       which is important for integrity of the blood-testis barrier (By
CC       similarity). Plays a role in myeloid homeostasis where it regulates the
CC       histone methylation state of bone marrow cells and expression of
CC       various genes involved in hematopoiesis. May function as a leukemia
CC       suppressor (By similarity). {ECO:0000250|UniProtKB:F8VPQ2,
CC       ECO:0000269|PubMed:14581478}.
CC   -!- SUBUNIT: Identified in mSin3A corepressor complexes together with
CC       SIN3A, SIN3B, RBBP4, RBBP7, SAP30, BRMS1, HDAC1 and HDAC2
CC       (PubMed:14581478). Interacts with BRMS1 (PubMed:14581478). Interacts
CC       with RB1 (PubMed:8414517, PubMed:8455946). Interacts with ARID4B
CC       (PubMed:17043311). Interacts with AR (PubMed:23487765).
CC       {ECO:0000269|PubMed:14581478, ECO:0000269|PubMed:17043311,
CC       ECO:0000269|PubMed:23487765, ECO:0000269|PubMed:8414517,
CC       ECO:0000269|PubMed:8455946}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00355,
CC       ECO:0000269|PubMed:8414517, ECO:0000269|PubMed:8455946}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=I;
CC         IsoId=P29374-1; Sequence=Displayed;
CC       Name=II;
CC         IsoId=P29374-2; Sequence=VSP_004373;
CC       Name=III;
CC         IsoId=P29374-3; Sequence=VSP_004371, VSP_004372;
CC   -!- DOMAIN: The function of the chromodomain-like region is uncertain
CC       (PubMed:22247551, PubMed:29408527). One study suggests that it mediates
CC       binding to lysine-methylated histone tails, with strongest affinity for
CC       H4K20me3 and H3K36me3 (PubMed:22247551). However, another study failed
CC       to find any interaction between this domain and histone H4K20me3
CC       peptide (PubMed:29408527). {ECO:0000269|PubMed:22247551,
CC       ECO:0000269|PubMed:29408527}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S66427; AAB28543.1; -; mRNA.
DR   EMBL; AL132989; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL139021; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S57153; AAB25833.1; -; mRNA.
DR   EMBL; S57160; AAB25834.1; -; mRNA.
DR   EMBL; S57162; AAB25835.2; -; mRNA.
DR   CCDS; CCDS45114.1; -. [P29374-2]
DR   CCDS; CCDS9732.1; -. [P29374-1]
DR   CCDS; CCDS9733.1; -. [P29374-3]
DR   PIR; I58383; I58383.
DR   RefSeq; NP_002883.3; NM_002892.3. [P29374-1]
DR   RefSeq; NP_075376.2; NM_023000.2. [P29374-2]
DR   RefSeq; NP_075377.2; NM_023001.2. [P29374-3]
DR   PDB; 2LCC; NMR; -; A=568-635.
DR   PDB; 2MAM; NMR; -; A=4-121.
DR   PDB; 2YRV; NMR; -; A=170-273.
DR   PDB; 6BPH; X-ray; 1.85 A; A=568-635.
DR   PDB; 6L87; NMR; -; A=171-414.
DR   PDBsum; 2LCC; -.
DR   PDBsum; 2MAM; -.
DR   PDBsum; 2YRV; -.
DR   PDBsum; 6BPH; -.
DR   PDBsum; 6L87; -.
DR   BMRB; P29374; -.
DR   SMR; P29374; -.
DR   BioGRID; 111861; 41.
DR   ComplexPortal; CPX-3321; SIN3A histone deacetylase complex.
DR   ComplexPortal; CPX-3322; SIN3B histone deacetylase complex.
DR   ComplexPortal; CPX-3323; SIN3A histone deacetylase complex, ES cell-specific variant.
DR   CORUM; P29374; -.
DR   DIP; DIP-463N; -.
DR   IntAct; P29374; 15.
DR   MINT; P29374; -.
DR   STRING; 9606.ENSP00000347602; -.
DR   ChEMBL; CHEMBL3709855; -.
DR   iPTMnet; P29374; -.
DR   PhosphoSitePlus; P29374; -.
DR   BioMuta; ARID4A; -.
DR   DMDM; 206729929; -.
DR   EPD; P29374; -.
DR   jPOST; P29374; -.
DR   MassIVE; P29374; -.
DR   MaxQB; P29374; -.
DR   PaxDb; P29374; -.
DR   PeptideAtlas; P29374; -.
DR   PRIDE; P29374; -.
DR   ProteomicsDB; 54556; -. [P29374-1]
DR   ProteomicsDB; 54557; -. [P29374-2]
DR   ProteomicsDB; 54558; -. [P29374-3]
DR   Antibodypedia; 11317; 60 antibodies.
DR   DNASU; 5926; -.
DR   Ensembl; ENST00000348476; ENSP00000344556; ENSG00000032219. [P29374-3]
DR   Ensembl; ENST00000355431; ENSP00000347602; ENSG00000032219. [P29374-1]
DR   Ensembl; ENST00000395168; ENSP00000378597; ENSG00000032219. [P29374-2]
DR   Ensembl; ENST00000431317; ENSP00000397368; ENSG00000032219. [P29374-3]
DR   GeneID; 5926; -.
DR   KEGG; hsa:5926; -.
DR   UCSC; uc001xdo.4; human. [P29374-1]
DR   CTD; 5926; -.
DR   DisGeNET; 5926; -.
DR   GeneCards; ARID4A; -.
DR   HGNC; HGNC:9885; ARID4A.
DR   HPA; ENSG00000032219; Low tissue specificity.
DR   MIM; 180201; gene.
DR   neXtProt; NX_P29374; -.
DR   OpenTargets; ENSG00000032219; -.
DR   PharmGKB; PA34249; -.
DR   VEuPathDB; HostDB:ENSG00000032219.18; -.
DR   eggNOG; KOG2744; Eukaryota.
DR   eggNOG; KOG3001; Eukaryota.
DR   GeneTree; ENSGT00940000156159; -.
DR   HOGENOM; CLU_007419_1_0_1; -.
DR   InParanoid; P29374; -.
DR   OMA; SEKTEWY; -.
DR   OrthoDB; 329541at2759; -.
DR   PhylomeDB; P29374; -.
DR   TreeFam; TF106427; -.
DR   PathwayCommons; P29374; -.
DR   Reactome; R-HSA-3214815; HDACs deacetylate histones.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SIGNOR; P29374; -.
DR   BioGRID-ORCS; 5926; 24 hits in 1030 CRISPR screens.
DR   ChiTaRS; ARID4A; human.
DR   EvolutionaryTrace; P29374; -.
DR   GeneWiki; ARID4A; -.
DR   GenomeRNAi; 5926; -.
DR   Pharos; P29374; Tbio.
DR   PRO; PR:P29374; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P29374; protein.
DR   Bgee; ENSG00000032219; Expressed in sural nerve and 233 other tissues.
DR   ExpressionAtlas; P29374; baseline and differential.
DR   Genevisible; P29374; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:GDB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0017053; C:transcription repressor complex; IDA:GDB.
DR   GO; GO:0003677; F:DNA binding; IDA:GDB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0048821; P:erythrocyte development; IEA:Ensembl.
DR   GO; GO:0097368; P:establishment of Sertoli cell barrier; IEA:Ensembl.
DR   GO; GO:0080182; P:histone H3-K4 trimethylation; IEA:Ensembl.
DR   GO; GO:0036124; P:histone H3-K9 trimethylation; IEA:Ensembl.
DR   GO; GO:0034773; P:histone H4-K20 trimethylation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:GDB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0006349; P:regulation of gene expression by genetic imprinting; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.150.60; -; 1.
DR   InterPro; IPR001606; ARID_dom.
DR   InterPro; IPR036431; ARID_dom_sf.
DR   InterPro; IPR016197; Chromo-like_dom_sf.
DR   InterPro; IPR000953; Chromo/chromo_shadow_dom.
DR   InterPro; IPR012603; RBB1NT.
DR   InterPro; IPR002999; Tudor.
DR   InterPro; IPR025995; Tudor-knot.
DR   Pfam; PF01388; ARID; 1.
DR   Pfam; PF08169; RBB1NT; 1.
DR   Pfam; PF11717; Tudor-knot; 1.
DR   SMART; SM00501; BRIGHT; 1.
DR   SMART; SM00298; CHROMO; 1.
DR   SMART; SM00333; TUDOR; 1.
DR   SUPFAM; SSF46774; SSF46774; 1.
DR   SUPFAM; SSF54160; SSF54160; 1.
DR   PROSITE; PS51011; ARID; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromatin regulator; Differentiation;
KW   DNA-binding; Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome;
KW   Spermatogenesis; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1257
FT                   /note="AT-rich interactive domain-containing protein 4A"
FT                   /id="PRO_0000200580"
FT   DOMAIN          309..401
FT                   /note="ARID"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00355"
FT   REGION          4..121
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:24379399"
FT   REGION          568..635
FT                   /note="Chromodomain-like"
FT                   /evidence="ECO:0000269|PubMed:22247551,
FT                   ECO:0000269|PubMed:29408527"
FT   REGION          951..964
FT                   /note="Retinoblastoma protein binding"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         676
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         716
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         864
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1109
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         1145
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        481
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364"
FT   CROSSLNK        513
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        718
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        738
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        759
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1106..1174
FT                   /note="Missing (in isoform III)"
FT                   /evidence="ECO:0000303|PubMed:8455946"
FT                   /id="VSP_004371"
FT   VAR_SEQ         1121..1174
FT                   /note="Missing (in isoform II)"
FT                   /evidence="ECO:0000303|PubMed:8455946"
FT                   /id="VSP_004373"
FT   VAR_SEQ         1175
FT                   /note="N -> D (in isoform III)"
FT                   /evidence="ECO:0000303|PubMed:8455946"
FT                   /id="VSP_004372"
FT   VARIANT         412
FT                   /note="H -> P (in dbSNP:rs34982206)"
FT                   /id="VAR_031566"
FT   VARIANT         724
FT                   /note="N -> S (in dbSNP:rs2230098)"
FT                   /id="VAR_031567"
FT   VARIANT         779
FT                   /note="T -> A (in dbSNP:rs1051858)"
FT                   /evidence="ECO:0000269|PubMed:8414517"
FT                   /id="VAR_031568"
FT   MUTAGEN         583
FT                   /note="Y->A: No effect on binding to trimethylated
FT                   lysines."
FT                   /evidence="ECO:0000269|PubMed:22247551"
FT   MUTAGEN         592
FT                   /note="Y->A: Significantly reduces affinity for
FT                   trimethylated lysines."
FT                   /evidence="ECO:0000269|PubMed:22247551"
FT   MUTAGEN         612
FT                   /note="Y->A: Abolishes binding to trimethylated lysines."
FT                   /evidence="ECO:0000269|PubMed:22247551"
FT   MUTAGEN         615
FT                   /note="W->A: Abolishes binding to trimethylated lysines."
FT                   /evidence="ECO:0000269|PubMed:22247551"
FT   MUTAGEN         619
FT                   /note="Y->A: Abolishes binding to trimethylated lysines."
FT                   /evidence="ECO:0000269|PubMed:22247551"
FT   CONFLICT        385
FT                   /note="V -> L (in Ref. 1; AAB28543)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        618
FT                   /note="R -> S (in Ref. 1; AAB28543)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        653
FT                   /note="K -> V (in Ref. 3; AAB25833/AAB25834/AAB25835)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1178
FT                   /note="D -> S (in Ref. 4; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1196..1201
FT                   /note="IRKYYM -> SENIICL (in Ref. 4; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   STRAND          8..10
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          15..20
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          23..42
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   TURN            43..45
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          48..52
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   TURN            53..55
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          56..58
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          65..69
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          75..93
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          98..102
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   HELIX           103..105
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          112..114
FT                   /evidence="ECO:0007744|PDB:2MAM"
FT   STRAND          177..182
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   STRAND          190..196
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   STRAND          211..218
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   STRAND          221..224
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   TURN            226..228
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   HELIX           239..244
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   HELIX           246..256
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   TURN            262..264
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   HELIX           269..272
FT                   /evidence="ECO:0007744|PDB:2YRV"
FT   STRAND          578..584
FT                   /evidence="ECO:0007744|PDB:6BPH"
FT   HELIX           586..588
FT                   /evidence="ECO:0007744|PDB:6BPH"
FT   STRAND          590..602
FT                   /evidence="ECO:0007744|PDB:6BPH"
FT   STRAND          605..612
FT                   /evidence="ECO:0007744|PDB:6BPH"
FT   HELIX           617..619
FT                   /evidence="ECO:0007744|PDB:6BPH"
FT   STRAND          621..624
FT                   /evidence="ECO:0007744|PDB:6BPH"
FT   HELIX           625..627
FT                   /evidence="ECO:0007744|PDB:6BPH"
SQ   SEQUENCE   1257 AA;  142752 MW;  5B3F6A5AFB7588CF CRC64;
     MKAADEPAYL TVGTDVSAKY RGAFCEAKIK TVKRLVKVKV LLKQDNTTQL VQDDQVKGPL
     RVGAIVETRT SDGSFQEAII SKLTDASWYT VVFDDGDERT LRRTSLCLKG ERHFAESETL
     DQLPLTNPEH FGTPVIAKKT NRGRRSSLPV TEDEKEEESS EEEDEDKRRL NDELLGKVVS
     VVSATERTEW YPALVISPSC NDDITVKKDQ CLVRSFIDSK FYSIARKDIK EVDILNLPES
     ELSTKPGLQK ASIFLKTRVV PDNWKMDISE ILESSSSDDE DGPAEENDEE KEKEAKKTEE
     EVPEEELDPE ERDNFLQQLY KFMEDRGTPI NKPPVLGYKD LNLFKLFRLV YHQGGCDNID
     SGAVWKQIYM DLGIPILNSA ASYNVKTAYR KYLYGFEEYC RSANIQFRTV HHHEPKVKEE
     KKDLEESMEE ALKLDQEMPL TEVKSEPEEN IDSNSESERE EIELKSPRGR RRIARDVNSI
     KKEIEEEKTE DKLKDNDTEN KDVDDDYETA EKKENELLLG RKNTPKQKEK KIKKQEDSDK
     DSDEEEEKSQ EREETESKCD SEGEEDEEDM EPCLTGTKVK VKYGRGKTQK IYEASIKSTE
     IDDGEVLYLV HYYGWNVRYD EWVKADRIIW PLDKGGPKKK QKKKAKNKED SEKDEKRDEE
     RQKSKRGRPP LKSTLSSNMP YGLSKTANSE GKSDSCSSDS ETEDALEKNL INEELSLKDE
     LEKNENLNDD KLDEENPKIS AHILKENDRT QMQPLETLKL EVGENEQIVQ IFGNKMEKTE
     EVKKEAEKSP KGKGRRSKTK DLSLEIIKIS SFGQNEAGSE PHIEAHSLEL SSLDNKNFSS
     ATEDEIDQCV KEKKLKRKIL GQSSPEKKIR IENGMEMTNT VSQERTSDCI GSEGMKNLNF
     EQHFERENEG MPSLIAESNQ CIQQLTSERF DSPAEETVNI PLKEDEDAMP LIGPETLVCH
     EVDLDDLDEK DKTSIEDVAV ESSESNSLVS IPPALPPVVQ HNFSVASPLT LSQDESRSVK
     SESDITIEVD SIAEESQEGL CERESANGFE TNVASGTCSI IVQERESREK GQKRPSDGNS
     GLMAKKQKRT PKRTSAAAKN EKNGTGQSSD SEDLPVLDNS SKCTPVKHLN VSKPQKLARS
     PARISPHIKD GEKDKHREKH PNSSPRTYKW SFQLNELDNM NSTERISFLQ EKLQEIRKYY
     MSLKSEVATI DRRRKRLKKK DREVSHAGAS MSSASSDTGM SPSSSSPPQN VLAVECR
//
